FDA’s Patient Engagement Advisory Committee milestone reflects push for patient input on drug development
The involvement of patients in the drug approval process has changed the status quo and most would argue, for the better.
Mark Senak
Mark Senak is senior vice president and partner at the international communications firm FleishmanHillard. Trained as lawyer, he works as a healthcare public affairs counselor and strategist providing regulatory communications counsel, message development, media training and crisis and issues management. For 10 years, he has written the blog ‘Eye on FDA’ providing patients, healthcare providers, journalists, analysts and members of the pharmaceutical industry with a one-stop-shop of industry analysis.